Lannett Company, Inc. (NYSE:LCI) has earned a consensus recommendation of “Hold” from the six brokerages that are currently covering the stock, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $9.63.

A number of brokerages have recently issued reports on LCI. Zacks Investment Research upgraded shares of Lannett from a “hold” rating to a “strong-buy” rating and set a $9.25 price target on the stock in a research report on Friday, August 30th. ValuEngine upgraded shares of Lannett from a “sell” rating to a “hold” rating in a research report on Tuesday, July 2nd. SunTrust Banks boosted their price target on shares of Lannett to $10.00 and gave the stock a “hold” rating in a research report on Thursday, August 29th. Finally, Roth Capital restated a “neutral” rating on shares of Lannett in a research report on Wednesday, August 28th.

NYSE:LCI traded down $0.21 during mid-day trading on Friday, hitting $13.89. 3,525,471 shares of the company’s stock were exchanged, compared to its average volume of 1,632,749. The company has a 50 day simple moving average of $7.99 and a 200-day simple moving average of $7.16. The company has a current ratio of 2.67, a quick ratio of 1.86 and a debt-to-equity ratio of 1.98. Lannett has a fifty-two week low of $3.33 and a fifty-two week high of $14.68. The firm has a market capitalization of $483.25 million, a P/E ratio of 5.91 and a beta of 2.19.

Lannett (NYSE:LCI) last issued its quarterly earnings results on Tuesday, August 27th. The company reported $0.37 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.21 by $0.16. The firm had revenue of $133.80 million for the quarter, compared to the consensus estimate of $120.28 million. Lannett had a negative net margin of 41.52% and a positive return on equity of 28.00%. The company’s revenue for the quarter was down 21.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.64 EPS. As a group, analysts expect that Lannett will post 1.18 earnings per share for the current year.

In related news, Director Patrick G. Lepore acquired 25,000 shares of the stock in a transaction dated Tuesday, September 3rd. The stock was bought at an average price of $9.82 per share, for a total transaction of $245,500.00. Following the purchase, the director now directly owns 201,340 shares of the company’s stock, valued at approximately $1,977,158.80. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Albert Paonessa III sold 16,195 shares of Lannett stock in a transaction on Monday, September 9th. The shares were sold at an average price of $12.54, for a total transaction of $203,085.30. Following the completion of the sale, the director now owns 45,945 shares of the company’s stock, valued at approximately $576,150.30. The disclosure for this sale can be found here. 12.57% of the stock is currently owned by insiders.

Large investors have recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA increased its stake in shares of Lannett by 105.4% in the 1st quarter. BNP Paribas Arbitrage SA now owns 7,046 shares of the company’s stock valued at $55,000 after acquiring an additional 3,615 shares in the last quarter. Sawtooth Solutions LLC bought a new stake in shares of Lannett in the 1st quarter valued at $197,000. Aperio Group LLC bought a new stake in shares of Lannett in the 2nd quarter valued at $49,000. Strs Ohio bought a new stake in shares of Lannett in the 2nd quarter valued at $603,000. Finally, Dupont Capital Management Corp increased its stake in shares of Lannett by 67.2% in the 2nd quarter. Dupont Capital Management Corp now owns 63,975 shares of the company’s stock valued at $388,000 after acquiring an additional 25,716 shares in the last quarter. Institutional investors own 98.56% of the company’s stock.

About Lannett

Lannett Company, Inc develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, suspension, soft gel, and injectable dosages.

Featured Story: Why is the conference call important?

Receive News & Ratings for Lannett Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett and related companies with MarketBeat.com's FREE daily email newsletter.